Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2003

View Archived Issues

Neurocrine Biosciences updates clinical development progress

FDA approves Humatrope for short stature

Positive opinion for new Zyprexa indication in Europe

Botulinum toxin A effective and safe in chronic myofascial pain

Phase II trial indicates promising efficacy for alemtuzumab in MF/SS

Beneficial effects found for EGF enema and oral mesalamine in ulcerative colitis

Additive antitumor effects described for SU-5416 and dalteparin in a glioblastoma cell line

Evidence of antitumor effects of DMXAA in refractory solid tumors

Dendreon completes acquisition of Corvas

Factive receives expanded FDA approval

Abbott and Dharmacon collaborate to develop siRNA library

Immunomodulator MM-093 enters phase I study

EPI-hNE4 designated European orphan drug for cystic fibrosis

Positive phase II results for AC-2592 in CHF

AVX-101 enters clinic

AltaStaph enters phase II in low-birth-weight neonates

Impavido improves cure rate in phase III cutaneous leishmaniasis trial

Enrollment completed in phase II trial of Ceplene in hepatitis C nonresponders

Cangene enters R&D partnership to develop hyperimmunes related to SARS

Human breast cancer growth inhibited by nocturnal melatonin

Bisphosphonates: methods for treatment of bone disorders claimed

Phosphatase inhibitors useful for diabetes claimed by Roche

BMS designs antiinflammatory agents with the ability to protect cartilage

Treatment of CNS disorders using 5-HT1D receptor ligands

Selective oxytocin receptor antagonists and their use reported by Japanese lab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.